2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 32

Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study
Abstract Number: 33

Analysis of Incidence Rates of Pulmonary Embolism in the Rheumatoid Arthritis Population Compared with the Non-Rheumatoid Arthritis Population
Abstract Number: 34

The Impact of Cardiovascular and Lung Disorder Morbidities on Physical Activity in People with Inflammatory Arthritis Compared to the General Population in the UK
Abstract Number: 35

Rheumatoid Arthritis As a Risk Factor for Cardiovascular Events Following Hospitalized Pneumonia; A Population-Based Cohort Study
Abstract Number: 36

The Incidence of Cardiovascular Events in Patients with Rheumatoid Arthritis: a 15 Years Observational Cohort Study
Abstract Number: 37

Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors
Abstract Number: 38

Impact of Obesity on the Disease Course of Rheumatoid Arthritis
Abstract Number: 39

Baseline Obesity and Subsequent Weight Loss Are Independently Associated with Cardiovascular Mortality in Established Rheumatoid Arthritis
Abstract Number: 40

Increased Mortality in Indigenous North Americans Persons with Rheumatoid Arthritis Is Partially Explained By Psychiatric and Physical Comorbidity: a Population Based Study
Abstract Number: 41

Trends in Non-Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis: Is There Room for Improvement?
Abstract Number: 42

Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?
Abstract Number: 43

Prevalence and Relevance of Depressive Symptoms in Patients with Rheumatic Diseases
Abstract Number: 44

The Prevalence of Depression and Anxiety in a Cross-Section of Rheumatological Conditions
Abstract Number: 45

Contributions of Social Determinants of Health on Probability of Remission in Early and Established Rheumatoid Arthritis Patients
Abstract Number: 46

Feasibility Study of Smartphone Data Collection for Cloudy with a Chance of Pain: Sustained Engagement for Daily Self-Reporting of Disease Severity in Rheumatoid Arthritis over Two Months

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].